Gotham’s RNA utility belt

Gotham enters RNA epigenetics with atomic-level screening system

Gotham Therapeutics Corp., the newest comer to the RNA epigenetics party, delves into the atomic-level biophysical properties of RNA-modifying enzymes to accelerate its small molecule discovery programs for cancer and other diseases.

RNA epigenetics is a growing area of research that spawned Storm Therapeutics Ltd. in 2016 and Accent Therapeutics Inc. and Gotham in 2017 (see “Accent on RNA” ; “Taking RNA Epigenetics by Storm”).

Read the full 646 word article

User Sign In